Biotech

© Getty Images

iOnctura reveals new translational cancer research

By Isabel Cameron

iOnctura, a clinical stage biotech company developing breakthrough therapies for cancer, has announced the peer-reviewed publication of translational research on the novel autotaxin (ATX) inhibitor IOA-289.